EVOTEC REACHES FIRST MILESTONE AND RECEIVES SUCCESS PAYMENT IN COLLABORATION WITH TAKEDA

A A

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30, "Evotec") announced today that the first milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda"). Evotec has granted Takeda exclusive rights in a novel target in Alzheimer's disease based on successful target identification and validation work triggering a milestone payment of a few millions Euro.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/6dc2c0f2af44ac21d5e3de6932f75a33.html)